BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11866009)

  • 1. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis.
    App EM; Baran D; Dab I; Malfroot A; Coffiner M; Vanderbist F; King M
    Eur Respir J; 2002 Feb; 19(2):294-302. PubMed ID: 11866009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase.
    Dasgupta B; King M
    Pediatr Pulmonol; 1996 Sep; 22(3):161-6. PubMed ID: 8893254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum.
    Sun F; Tai S; Lim T; Baumann U; King M
    Can Respir J; 2002; 9(6):401-6. PubMed ID: 12522485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deposition of nacystelyn from a dry powder inhaler in healthy volunteers and cystic fibrosis patients.
    Vanderbist F; Wery B; Baran D; Van Gansbeke B; Schoutens A; Moës AJ
    Drug Dev Ind Pharm; 2001; 27(3):205-12. PubMed ID: 11291200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of a new mucolytic N-acetylcysteine L-lysinate with N-acetylcysteine: airway epithelial function and mucus changes in dog.
    Tomkiewicz RP; App EM; De Sanctis GT; Coffiner M; Maes P; Rubin BK; King M
    Pulm Pharmacol; 1995 Dec; 8(6):259-65. PubMed ID: 8819180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.
    Noone PG; Hamblett N; Accurso F; Aitken ML; Boyle M; Dovey M; Gibson R; Johnson C; Kellerman D; Konstan MW; Milgram L; Mundahl J; Retsch-Bogort G; Rodman D; Williams-Warren J; Wilmott RW; Zeitlin P; Ramsey B;
    Pediatr Pulmonol; 2001 Aug; 32(2):122-8. PubMed ID: 11477729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride).
    Dietzsch HJ; Gottschalk B; Heyne K; Leupoid W; Wunderlich P
    Pediatrics; 1975 Jan; 55(1):96-100. PubMed ID: 1110869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucolytic treatment with N-acetylcysteine L-lysinate metered dose inhaler in dogs: airway epithelial function changes.
    Tomkiewicz RP; App EM; Coffiner M; Fossion J; Maes P; King M
    Eur Respir J; 1994 Jan; 7(1):81-7. PubMed ID: 8143836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro.
    Feng W; Garrett H; Speert DP; King M
    Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):710-4. PubMed ID: 9517580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis.
    Hofmann T; Senier I; Bittner P; Hüls G; Schwandt HJ; Lindemann H
    J Aerosol Med; 1997; 10(2):147-58. PubMed ID: 10168532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy: flutter vs autogenic drainage.
    App EM; Kieselmann R; Reinhardt D; Lindemann H; Dasgupta B; King M; Brand P
    Chest; 1998 Jul; 114(1):171-7. PubMed ID: 9674466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.
    Nash EF; Stephenson A; Ratjen F; Tullis E
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007168. PubMed ID: 19160327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rheological Properties of Cystic Fibrosis Bronchial Secretion and in Vitro Drug Permeation Study: The Effect of Sodium Bicarbonate.
    Stigliani M; Manniello MD; Zegarra-Moran O; Galietta L; Minicucci L; Casciaro R; Garofalo E; Incarnato L; Aquino RP; Del Gaudio P; Russo P
    J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):337-45. PubMed ID: 26741302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
    Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
    Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Tolerability, and Effects of Sodium Bicarbonate Inhalation in Cystic Fibrosis.
    Gomez CCS; Parazzi PLF; Clinckspoor KJ; Mauch RM; Pessine FBT; Levy CE; Peixoto AO; Ribeiro MÂGO; Ribeiro AF; Conrad D; Quinton PM; Marson FAL; Ribeiro JD
    Clin Drug Investig; 2020 Feb; 40(2):105-117. PubMed ID: 31721070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
    Deterding R; Retsch-Bogart G; Milgram L; Gibson R; Daines C; Zeitlin PL; Milla C; Marshall B; Lavange L; Engels J; Mathews D; Gorden J; Schaberg A; Williams J; Ramsey B;
    Pediatr Pulmonol; 2005 Apr; 39(4):339-48. PubMed ID: 15704203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
    King M; Dasgupta B; Tomkiewicz RP; Brown NE
    Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis.
    Homnick DN; Marks JH; Rubin BK
    J Aerosol Med; 2007; 20(1):45-9. PubMed ID: 17388752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
    Moss RB; Mayer-Hamblett N; Wagener J; Daines C; Hale K; Ahrens R; Gibson RL; Anderson P; Retsch-Bogart G; Nasr SZ; Noth I; Waltz D; Zeitlin P; Ramsey B; Starko K
    Pediatr Pulmonol; 2005 Mar; 39(3):209-18. PubMed ID: 15573395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.